Plain-English translation of NCT07415655 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether albumin — a natural protein found in blood — can help protect your brain when given during emergency treatment for ischemic stroke (a stroke caused by a blood clot). Researchers believe this medication may reduce brain damage in the area surrounding the main clot by supporting the tiny blood vessels in your brain. The treatment has been safely used in medicine for 80 years.
When a stroke happens, not all the brain damage occurs immediately — some brain tissue around the clot can still be saved if protected in time. This trial is testing whether the medication can help reduce that secondary damage and improve your chances of a better recovery.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to receive either the albumin treatment or a placebo (inactive substance) during your emergency stroke care procedure. The screening, randomization, and treatment happen within hours. You will then spend time in the intensive care unit and hospital ward, followed by outpatient follow-up visits for 90 days. Your total participation lasts about 3 months.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
Czechia
Sponsor
University Hospital Hradec Kralove
Enrollment target
~100 participants
Started
February 2026
Primary completion
February 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
David Astapenko, M.D., Ph.D., MBA
University Hospital Hradec Kralove
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.